12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Clolar clofarabine regulatory update

Genzyme said FDA's Oncologic Drugs Advisory Committee will discuss an sNDA for Clolar clofarabine to treat acute myeloid leukemia (AML) in untreated patients ages 60 and...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >